Cart
sales@molnova.com
GSK 635416A
CAS No. 944729-29-7
GSK 635416A( GSK635416A )
Catalog No. M16767 CAS No. 944729-29-7
GSK 635416A is a novel ATM inhibitor with highly selective radiosensitizing activity, inhibits radiation induced phosphorylation of ATM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGSK 635416A
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK 635416A is a novel ATM inhibitor with highly selective radiosensitizing activity, inhibits radiation induced phosphorylation of ATM.
-
DescriptionGSK 635416A is a novel ATM inhibitor with highly selective radiosensitizing activity, inhibits radiation induced phosphorylation of ATM; exhibits virtually no cytotoxicity in the absence of radiation and in normal fibroblast cells, enhances IR effect in radiosensitizing HNSCC cell lines but not in normal fibroblast BJ-ET cells in combined with olaparib.
-
In Vitro——
-
In Vivo——
-
SynonymsGSK635416A
-
PathwayCell Cycle/DNA Damage
-
TargetATM/ATR
-
RecptorATM/ATR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number944729-29-7
-
Formula Weight453.532
-
Molecular FormulaC24H24FN3O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name2-amino-5-(4-fluorophenyl)-N-methyl-3-(4-pyrrolidin-1-ylsulfonylphenyl)benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dohmen AJC, et al. Oncotarget. 2017 May 19;8(43):73925-73937.
molnova catalog
related products
-
AZ20
AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.
-
VE822
VE-822 is an ATR inhibitor with IC50 of 19 nM in HT29 cells.
-
BAY-1895344
BAY-1895344 is a potent, selective, orally active ATR inhibitor with low-nanomolar potency; potently inhibits the proliferation of a broad spectrum of human tumor cell lines with mean IC50 of 78 nM; inhibits hydroxyurea-induced H2AX phosphorylation, exhibits strong in vivo anti-tumor efficacy in monotherapy in a variety of xenograft models.Blood Cancer,Phase 1 Clinical
